Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

NCT06543069 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Malignant Peritoneal Mesothelioma, Advanced

Interventions

DRUG: Sintilimab, Bevacizumab , Pemetrexed , Cisplatin

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences